564 related articles for article (PubMed ID: 30944079)
21. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
[TBL] [Abstract][Full Text] [Related]
22. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
23. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
[TBL] [Abstract][Full Text] [Related]
24. EGFR activation limits the response of liver cancer to lenvatinib.
Jin H; Shi Y; Lv Y; Yuan S; Ramirez CFA; Lieftink C; Wang L; Wang S; Wang C; Dias MH; Jochems F; Yang Y; Bosma A; Hijmans EM; de Groot MHP; Vegna S; Cui D; Zhou Y; Ling J; Wang H; Guo Y; Zheng X; Isima N; Wu H; Sun C; Beijersbergen RL; Akkari L; Zhou W; Zhai B; Qin W; Bernards R
Nature; 2021 Jul; 595(7869):730-734. PubMed ID: 34290403
[TBL] [Abstract][Full Text] [Related]
25. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
Watanabe T; Koyama N
Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
28. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
Hu Q; Hu X; Zhang L; Zhao Y; Li L
Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
[TBL] [Abstract][Full Text] [Related]
29. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Watanabe Miyano S; Yamamoto Y; Kodama K; Miyajima Y; Mikamoto M; Nakagawa T; Kuramochi H; Funasaka S; Nagao S; Sugi NH; Okamoto K; Minoshima Y; Nakatani Y; Karoji Y; Ohashi I; Yamane Y; Okada T; Matsushima T; Matsui J; Iwata M; Uenaka T; Tsuruoka A
Mol Cancer Ther; 2016 Nov; 15(11):2630-2639. PubMed ID: 27535969
[TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
31. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
32. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Kaibori M; Sakai K; Ishizaki M; Matsushima H; De Velasco MA; Matsui K; Iida H; Kitade H; Kwon AH; Nagano H; Wada H; Haji S; Tsukamoto T; Kanazawa A; Takeda Y; Takemura S; Kubo S; Nishio K
Oncotarget; 2016 Aug; 7(31):49091-49098. PubMed ID: 27384874
[TBL] [Abstract][Full Text] [Related]
33. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
34. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
[TBL] [Abstract][Full Text] [Related]
35. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
36. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways.
Shao RX; Otsuka M; Kato N; Taniguchi H; Hoshida Y; Moriyama M; Kawabe T; Omata M
Gastroenterology; 2005 Jan; 128(1):86-95. PubMed ID: 15633126
[TBL] [Abstract][Full Text] [Related]
37. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract][Full Text] [Related]
38. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
39. Lenvatinib mesylate to treat hepatocellular carcinoma.
Ielasi L; Tovoli F; Piscaglia F
Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
[TBL] [Abstract][Full Text] [Related]
40. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
